

Product datasheet for TL315228V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Epigen (EPGN) Human shRNA Lentiviral Particle (Locus ID 255324)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: Epigen (EPGN) Human shRNA Lentiviral Particle (Locus ID 255324)

Locus ID: 255324

Synonyms: ALGV3072; EPG; epigen; PRO9904

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: LOC255324 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1

scramble control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 001013442, NM 001270989, NM 001270990, NM 001270991, NM 001270992,

NM 001270993, NR 073114, NR 073117, NM 001013442.1, NM 001270993.1,

NM 001270991.1, NM 001270992.1, NM 001270990.1, NM 001270989.1, BC127938, BC127939, BC140431, BC146547, NM 001270990.2, NM 001270992.2, NM 001270989.2,

NM 001270991.2, NM 001270993.2

UniProt ID: O6UW88

Summary: The protein encoded by this gene is a member of the epidermal growth factor family.

Members of this family are ligands for the epidermal growth factor receptor and play a role in

cell survival, proliferation and migration. This protein has been reported to have high mitogenic activity but low affinity for its receptor. Expression of this transcript and protein have been reported in cancer specimens of the breast, bladder, and prostate. Alternative

splicing results in multiple transcript variants. [provided by RefSeq, Aug 2012]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Epigen (EPGN) Human shRNA Lentiviral Particle (Locus ID 255324) - TL315228V

Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).